View in EDS

Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.

Saved in:
Bibliographic Details
Title: Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
Authors: Moll K; IBM Consulting, Bethesda, MD, USA., Lufkin B; Acumen LLC, Burlingame, CA, USA., Fingar KR; IBM Consulting, Bethesda, MD, USA., Ke Zhou C; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA., Tworkoski E; Acumen LLC, Burlingame, CA, USA., Shi C; Acumen LLC, Burlingame, CA, USA., Hobbi S; IBM Consulting, Bethesda, MD, USA., Hu M; Acumen LLC, Burlingame, CA, USA., Sheng M; IBM Consulting, Bethesda, MD, USA., McCarty J; IBM Consulting, Bethesda, MD, USA., Shangguan S; Acumen LLC, Burlingame, CA, USA., Burrell T; IBM Consulting, Bethesda, MD, USA., Chillarige Y; Acumen LLC, Burlingame, CA, USA., Beers J; IBM Consulting, Bethesda, MD, USA., Saunders-Hastings P; Gevity Inc, an Accenture Company, Ottawa, Canada., Muthuri S; IBM Consulting, Bethesda, MD, USA., Edwards K; IBM Consulting, Bethesda, MD, USA., Black S; IBM Consulting, Bethesda, MD, USA., Kelman J; Centers for Medicare & Medicaid Services, Baltimore, MD, USA., Reich C; IQVIA, Falls Church, VA, USA., Amend KL; Optum Epidemiology, Boston, MA, USA., Djibo DA; Aetna, Blue Bell, PA, USA., Beachler D; HealthCore, Inc, Wilmington, DE, USA., Ogilvie RP; Optum Epidemiology, Boston, MA, USA., Secora A; IQVIA, Falls Church, VA, USA., McMahill-Walraven CN; Aetna, Blue Bell, PA, USA., Seeger JD; Optum Epidemiology, Boston, MA, USA., Lloyd P; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA., Thompson D; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA., Dimova R; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA., MaCurdy T; Acumen LLC, Burlingame, CA, USA; Department of Economics, Stanford University, Stanford, CA, USA., Obidi J; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA., Anderson S; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA., Forshee R; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA., Wong HL; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA., Shoaibi A; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA. Electronic address: Azadeh.Shoaibi@fda.hhs.gov.
Source: Vaccine [Vaccine] 2023 Jan 09; Vol. 41 (2), pp. 333-353. Date of Electronic Publication: 2022 Nov 08.
Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36404170
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Moll+K%22">Moll K</searchLink>; IBM Consulting, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Lufkin+B%22">Lufkin B</searchLink>; Acumen LLC, Burlingame, CA, USA.<br /><searchLink fieldCode="AU" term="%22Fingar+KR%22">Fingar KR</searchLink>; IBM Consulting, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Ke+Zhou+C%22">Ke Zhou C</searchLink>; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22Tworkoski+E%22">Tworkoski E</searchLink>; Acumen LLC, Burlingame, CA, USA.<br /><searchLink fieldCode="AU" term="%22Shi+C%22">Shi C</searchLink>; Acumen LLC, Burlingame, CA, USA.<br /><searchLink fieldCode="AU" term="%22Hobbi+S%22">Hobbi S</searchLink>; IBM Consulting, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Hu+M%22">Hu M</searchLink>; Acumen LLC, Burlingame, CA, USA.<br /><searchLink fieldCode="AU" term="%22Sheng+M%22">Sheng M</searchLink>; IBM Consulting, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22McCarty+J%22">McCarty J</searchLink>; IBM Consulting, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Shangguan+S%22">Shangguan S</searchLink>; Acumen LLC, Burlingame, CA, USA.<br /><searchLink fieldCode="AU" term="%22Burrell+T%22">Burrell T</searchLink>; IBM Consulting, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Chillarige+Y%22">Chillarige Y</searchLink>; Acumen LLC, Burlingame, CA, USA.<br /><searchLink fieldCode="AU" term="%22Beers+J%22">Beers J</searchLink>; IBM Consulting, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Saunders-Hastings+P%22">Saunders-Hastings P</searchLink>; Gevity Inc, an Accenture Company, Ottawa, Canada.<br /><searchLink fieldCode="AU" term="%22Muthuri+S%22">Muthuri S</searchLink>; IBM Consulting, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Edwards+K%22">Edwards K</searchLink>; IBM Consulting, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Black+S%22">Black S</searchLink>; IBM Consulting, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Kelman+J%22">Kelman J</searchLink>; Centers for Medicare & Medicaid Services, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Reich+C%22">Reich C</searchLink>; IQVIA, Falls Church, VA, USA.<br /><searchLink fieldCode="AU" term="%22Amend+KL%22">Amend KL</searchLink>; Optum Epidemiology, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Djibo+DA%22">Djibo DA</searchLink>; Aetna, Blue Bell, PA, USA.<br /><searchLink fieldCode="AU" term="%22Beachler+D%22">Beachler D</searchLink>; HealthCore, Inc, Wilmington, DE, USA.<br /><searchLink fieldCode="AU" term="%22Ogilvie+RP%22">Ogilvie RP</searchLink>; Optum Epidemiology, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Secora+A%22">Secora A</searchLink>; IQVIA, Falls Church, VA, USA.<br /><searchLink fieldCode="AU" term="%22McMahill-Walraven+CN%22">McMahill-Walraven CN</searchLink>; Aetna, Blue Bell, PA, USA.<br /><searchLink fieldCode="AU" term="%22Seeger+JD%22">Seeger JD</searchLink>; Optum Epidemiology, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Lloyd+P%22">Lloyd P</searchLink>; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22Thompson+D%22">Thompson D</searchLink>; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22Dimova+R%22">Dimova R</searchLink>; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22MaCurdy+T%22">MaCurdy T</searchLink>; Acumen LLC, Burlingame, CA, USA; Department of Economics, Stanford University, Stanford, CA, USA.<br /><searchLink fieldCode="AU" term="%22Obidi+J%22">Obidi J</searchLink>; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22Anderson+S%22">Anderson S</searchLink>; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22Forshee+R%22">Forshee R</searchLink>; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22Wong+HL%22">Wong HL</searchLink>; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA.<br /><searchLink fieldCode="AU" term="%22Shoaibi+A%22">Shoaibi A</searchLink>; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD, USA. Electronic address: Azadeh.Shoaibi@fda.hhs.gov.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228406899%22">Vaccine</searchLink> [Vaccine] 2023 Jan 09; Vol. 41 (2), pp. 333-353. <i>Date of Electronic Publication: </i>2022 Nov 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, U.S. Gov't, P.H.S.
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8406899 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-2518 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220264410X%22">0264410X </searchLink><i>NLM ISO Abbreviation: </i>Vaccine <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36404170
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.vaccine.2022.11.003
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 333
    Titles:
      – TitleFull: Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Moll K
      – PersonEntity:
          Name:
            NameFull: Lufkin B
      – PersonEntity:
          Name:
            NameFull: Fingar KR
      – PersonEntity:
          Name:
            NameFull: Ke Zhou C
      – PersonEntity:
          Name:
            NameFull: Tworkoski E
      – PersonEntity:
          Name:
            NameFull: Shi C
      – PersonEntity:
          Name:
            NameFull: Hobbi S
      – PersonEntity:
          Name:
            NameFull: Hu M
      – PersonEntity:
          Name:
            NameFull: Sheng M
      – PersonEntity:
          Name:
            NameFull: McCarty J
      – PersonEntity:
          Name:
            NameFull: Shangguan S
      – PersonEntity:
          Name:
            NameFull: Burrell T
      – PersonEntity:
          Name:
            NameFull: Chillarige Y
      – PersonEntity:
          Name:
            NameFull: Beers J
      – PersonEntity:
          Name:
            NameFull: Saunders-Hastings P
      – PersonEntity:
          Name:
            NameFull: Muthuri S
      – PersonEntity:
          Name:
            NameFull: Edwards K
      – PersonEntity:
          Name:
            NameFull: Black S
      – PersonEntity:
          Name:
            NameFull: Kelman J
      – PersonEntity:
          Name:
            NameFull: Reich C
      – PersonEntity:
          Name:
            NameFull: Amend KL
      – PersonEntity:
          Name:
            NameFull: Djibo DA
      – PersonEntity:
          Name:
            NameFull: Beachler D
      – PersonEntity:
          Name:
            NameFull: Ogilvie RP
      – PersonEntity:
          Name:
            NameFull: Secora A
      – PersonEntity:
          Name:
            NameFull: McMahill-Walraven CN
      – PersonEntity:
          Name:
            NameFull: Seeger JD
      – PersonEntity:
          Name:
            NameFull: Lloyd P
      – PersonEntity:
          Name:
            NameFull: Thompson D
      – PersonEntity:
          Name:
            NameFull: Dimova R
      – PersonEntity:
          Name:
            NameFull: MaCurdy T
      – PersonEntity:
          Name:
            NameFull: Obidi J
      – PersonEntity:
          Name:
            NameFull: Anderson S
      – PersonEntity:
          Name:
            NameFull: Forshee R
      – PersonEntity:
          Name:
            NameFull: Wong HL
      – PersonEntity:
          Name:
            NameFull: Shoaibi A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 01
              Text: 2023 Jan 09
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1873-2518
          Numbering:
            – Type: volume
              Value: 41
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Vaccine
              Type: main
ResultId 1